Impact of COVID-19 on Benzodiazepine Anticonvulsant Drugs Market

Benzodiazepine anticonvulsant drugs are effective in preventing or controlling seizures or convulsions. Various types of gamma-amino-butyric acid-A (GABA-A) receptor subtypes are enhanced by the action of benzodiazepines. Different subtypes of benzodiazepines have different effects due to difference in their affinity. According to a research study, α-1-GABA-A, one of the GABA-A subtypes, is responsible for moderating sedation, amnesia, and anticonvulsant activity. α-2-GABA-A, another subtype, moderates anxiety. Benzodiazepine anticonvulsant drugs have high affinity for α-1-GABA-A. Examples of benzodiazepine anticonvulsant drugs are midazolam, lorazepam, diazepam, clorazepate, clonazepam, and clobazam.

Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=45177

Seizures are also known as convulsions. The patient experiences jerking of legs, arms, or face. Various types of seizures could happen to people of any age, lasting for few minutes or seconds. Minor seizures can also be extremely dangerous if these occur while driving or swimming. Seizures that affect only one part of the brain are known as simple partial seizures or simple focal seizures. During a seizure, there may be loss of awareness, loss of memory, or mental confusion. Such seizures are known as focal dyscognitive seizures.

Request a Sample of Benzodiazepine Anticonvulsant Drugs Market: https://www.transparencymarketresearch.com/checkout.php?rep_id=45177<ype=S

Rise in prevalence of seizures across the world drives the global benzodiazepine anticonvulsants drugs market. According to Healthline Media and Epilepsy Foundation of America, every year, nearly 150,000 people in the U.S. are diagnosed with CNS disorder which causes seizures. Healthline Media also stated that one in 26 people will be diagnosed with seizures in their lifetimes. Epilepsy is defined as having two or more unprovoked seizures.
According to the WHO, up to 10% of people across the world have one seizure during their lifetimes. The WHO also stated that nearly 50 million people are living with epilepsy across the globe presently.
Every year, between 30 and 50 per 100,000 people are diagnosed with new cases of epilepsy in high-income countries, and this number is two times higher among low and middle income countries. Ketogenic diet is anticipated to restrain the global benzodiazepine anticonvulsants drugs market. A study conducted by the National Center for Biotechnology Information, U.S. National Library of Medicine revealed that ketogenic diet reduced the chances of seizures in children.

Request for Analysis of COVID19 Impact on Benzodiazepine Anticonvulsant Drugs Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=45177

The global benzodiazepine anticonvulsant drugs market can be segmented based on indication, distribution channel, and region. In terms of indication, the market can be bifurcated into generalized seizures and focal (partial) seizures. Generalized seizures can be classified into tonic-clonic seizures, atonic seizures, myoclonic seizures, clonic seizures, and tonic seizures. Focal seizures can be categorized into dyscognitive focal seizures and simple focal seizures. Based on distribution channel, the global benzodiazepine anticonvulsant drugs market can be divided into retail pharmacies, online pharmacies, and hospital pharmacies.

Geographically, the global benzodiazepine anticonvulsant drugs market can be segmented into Latin America, Asia Pacific, Europe, North America, and Middle East & Africa. North America held the largest market share in 2017, due to new drug launches and increased research and development on benzodiazepine anticonvulsants drugs. Europe held the second largest market share in 2017, owing to increased promotional activities to create awareness regarding the benefits associated with the use of benzodiazepine anticonvulsant drugs in the region. The market in Asia Pacific is anticipated to expand at the fastest growth rate during the forecast period owing to increase in government activities to increase awareness about benzodiazepine anticonvulsants drugs especially in countries such as China and India. Japan held significant market share in Asia Pacific in 2017 owing to high geriatric population in the country. The market in Middle East & Africa and Latin America is anticipated to grow at a moderate pace during the forecast period owing to rise in government initiatives regarding benzodiazepine anticonvulsants drugs in the regions.

Pre-Book Benzodiazepine Anticonvulsant Drugs Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=45177<ype=S

Key players in the global benzodiazepine anticonvulsant drugs market include F. Hoffmann-La Roche Ltd., MEDA Manufacturing GmbH, Valeant Pharmaceuticals International, Inc., and H. Lundbeck A/S.

Read More Reports: https://www.prnewswire.com/news-releases/replacement-of-traditional-treatment-methods-with-cold-laser-therapies-to-boost-growth-rate-north-america-to-bring-immense-growth-opportunities-for-cold-laser-therapy-market-projects-tmr-301105756.html

Contact

Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com/

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of analysts, researchers, and consultants, uses proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

This release was published on openPR.